Ruprecht-karls-universitat Heidelberg

Merck Patent Gmbh

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Deutsches Krebsforschungszentrum

Novartis Ag

Universitat Heidelberg

Ruprecht-karls-universität

Amcure Gmbh

Ruprecht-karls-universität-heidelberg (rektorat)

Walter Mier

Uwe Haberkorn

Stephan Urban

Michael Eisenhut

Matthias Eder

Klaus Kopka

Martina Benesova

Martin Schäfer

Ulrike Bauder-Wüst

Armin Kuebelbeck

Gregor Larbig

Stefan Arnold

Manfred Wiessler

Philipp Uhl

Stefan Mehrle

Gert Fricker

Véronique Orian-Rousseau

Matthias Strieker

Barbro Beijer

Ulrike Wagner-Utermann

Stefan Johannes Martin

Yi Ni

Hans-Christian Kliem

Peter P Nawroth

Thomas H Fleming

Clemens Kratochwil

Joseph Antonius Maria Eisenbarth

Alexandra Matzke-Ogi

Markus Gschrey

Willi Von Der Lieth

Marek Los

Klaus Michael Debatin

Simone Fulda

Thomas Lindner

Max Sauter

Sebastian Brings

Thomas Müller

Vasileios Askoxylakis

Frieder Helm

Thomas Mueller

Martin Schafer

Ulrike Bauder-Wust

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.

Cyclic NTCP-targeting peptides and their uses as entry inhibitors

The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine-containing protein. Preferred scavenger compounds are said cyclic peptides comprising a specific amino acid motif and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.

Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels

The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.

Liposomal formulation for the oral hepatic delivery of drugs

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.

CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.

Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules

The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.

Hydrophobic modified peptides and their use for liver specific targeting

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

The present invention relates to a conjugate containing at least one kidney-selective carrier molecule and at least one active compound which has a protective action for the kidney against nephrotoxic active compounds, to a process for the preparation of the conjugate, to the use thereof for the protection of the kidney against nephrotoxic active compounds, and to a medicament comprising the conjugate.

Conjugates for protection from nephrotoxic active substances

The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.

Hydrophobic modified peptides for liver specific diagnosis

The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient.

Conjugates of proteins and multivalent cell-penetrating peptides and their uses

The present invention relates to a peptide which consists of more than 50% of sequence sections of the formula -(A-B-C)-, and to a conjugate containing the peptide and at least one covalently bonded active compound, and to a process for the preparation of the conjugate. The present invention furthermore relates to the use of the peptide and the conjugate for targeting of the kidney, and to a medicament comprising the peptide or conjugate.

Peptides and peptide/active compound conjugates for renal targeting

Growing community of inventors

Bensheim, Germany

Walter Mier